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Transforming growth factor b has been implicated as
a mediator of excessive extracellular matrix deposi-
tion in scar tissue and ®brosis, including systemic
sclerosis. To further characterize the mechanism of
collagen gene expression in systemic sclerosis and
healthy skin ®broblasts, we examined the role of p38
MAPK signaling in collagen gene regulation by
transforming growth factor b. Treatment of dermal
®broblasts with transforming growth factor b
resulted in a prolonged activation of p38 MAPK.
Furthermore, a speci®c inhibitor of p38 suppressed
transforming growth factor b stimulation of collagen
type I mRNA and the a2(I) collagen promoter
activity. To further probe the role of p38 in collagen
regulation by transforming growth factor b, we util-
ized an expression vector containing p38a cDNA.
Ectopic expression of p38a enhanced COL1A2 pro-
moter activity and potentiated transforming growth
factor b stimulation of this promoter. The p38
response element in the COL1A2 promoter over-
lapped with the previously characterized transform-
ing growth factor b response element. Consistent
with these observations, collagen type I mRNA and
protein levels were increased in transforming-
growth-factor-b-stimulated ®broblasts transduced
with an adenoviral vector expressing p38a. To deter-
mine the possible role of p38 in abnormal collagen
production by systemic sclerosis ®broblasts, p38
protein levels were compared in systemic sclerosis
and healthy skin ®broblasts. Both cell types exhibited
similar total levels of p38 MAPK and similar kinetics
of p38 activation in response to transforming growth
factor b. In conclusion, this study demonstrates a
costimulatory role for p38 MAPK in transforming
growth factor b induction of the collagen type I
gene. Expression levels and activation status of p38
are not consistently elevated in systemic sclerosis
®broblasts suggesting that the p38 MAPK pathway is
not dysregulated in systemic sclerosis ®broblasts.
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T
ransforming growth factor b (TGF-b) is a member of
a large family of growth factors with diverse functions
in embryonic and adult tissues (Massague and Chen,
2000). TGF-b plays a critical role as a regulator of
immune cell function, epithelial cell growth, and
extracellular matrix (ECM) deposition (Massague, 1990).
Overproduction of TGF-b is associated with excessive deposition
of scar tissue and ®brosis (Blobe et al, 2000). TGF-b signals through
a heteromeric receptor complex of type I and II receptor serine-
threonine kinases. Recent studies indicate that the TGF-b signaling
pathway interacts with other cellular pathways in a tissue-speci®c
manner. These interactions may be of critical importance to explain
the pleiotropic and often opposite effects of TGF-b in various
tissues. There are numerous examples of the modulation of the
TGF-b pathway by Ras-ERK (extracellular signal regulated kinase)
signaling. Antagonistic effects of Ras and TGF-b pathways have
been demonstrated in development and in epithelial cell prolifera-
tion. There are also examples of cooperation between these two
pathways, however (Massague and Chen, 2000).
The three major groups of the mammalian MAP kinase family
include ERKs, c-jun N-terminal or stress-activated protein kinases
(JNK/SAPKs), and p38 kinases (Firestein and Manning, 1999). The
involvement of the members of each MAPK subfamily has been
demonstrated in collagen gene regulation in various experimental
systems (Chen and Davis, 1999; Hayashida et al, 1999; Ivaska et al,
1999). Furthermore, ERKs and p38 have been shown to interact
with the TGF-b pathway in the regulation of ECM deposition and
turnover (Hayashida et al, 1999; Douillet et al, 2000). The role of
p38 in collagen production has previously been investigated. For
example, it has been shown that a2b1 integrin dependent
activation of COL1A1 expression in three-dimensional collagen
gels is mediated by p38 in the osteosarcoma cell line Saos-2 (Ivaska
et al, 1999). Collagen production is downregulated in dermal
®broblasts cultured within three-dimensional collagen gels, how-
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ever (Langholz et al, 1995). Therefore, the ®ndings from the Saos-2
cell line may not be directly applicable to dermal ®broblasts. On the
other hand, expression of matrix metalloproteinase 1 (MMP-1) and
MMP-13 is elevated in dermal ®broblasts cultured in collagen gels
(Langholz et al, 1995; Ravanti et al, 1999b). Furthermore,
induction of MMP-13 in this system depends on the activity of
p38 and could be downregulated by TGF-b (Ravanti et al, 1999b).
In contrast to human dermal ®broblasts, TGF-b induces MMP-13
via p38 in human gingival ®broblasts (Ravanti et al, 1999a). Because
various cell types, including human ®broblasts isolated from
different tissues, respond differently to p38, cellular context is
crucial in determining the effects of p38 on matrix gene regulation.
Previous studies have indicated that ®broblasts isolated from
systemic sclerosis (SSc) lesions exhibit increased levels of collagen
(Jelaska et al, 1996). There is also evidence that suggests alterations
in TGF-b signaling in SSc ®broblasts (Yamakage et al, 1992;
Kawakami et al, 1998; Jelaska and Korn, 2000). As p38 may be
involved in TGF-b regulation of ECM deposition, this study was
undertaken to examine the role of p38 in TGF-b regulation of
collagen production in SSc and healthy control ®broblasts. This
study demonstrates that p38 cooperates with TGF-b in stimulation
of collagen protein, mRNA, and COL1A2 promoter activity in
dermal ®broblasts. Furthermore, TGF-b induces prolonged activ-
ation of p38 in both SSc and control ®broblasts. The total p38
levels and the magnitude of p38 activation do not differ signi®c-
antly in SSc and healthy skin ®broblasts, however, suggesting that
this pathway is not dysregulated in SSc ®broblasts.
MATERIALS AND METHODS
Cell cultures Upon informed consent and in compliance with the
Institutional Review Board for Human Studies, ®broblasts were obtained
by skin biopsy from the affected areas (dorsal forearm) of patients with
diffuse cutaneous SSc (three females and two males; median age 45 y,
range 30±62 y). Modi®ed Rodnan skin scores ranged from 10 to 34.
The duration of skin thickening was from 4 mo to 1 y for all patients
tested. All patients ful®lled the criteria of the American College of
Rheumatology for SSc and had not undergone any treatment for SSc at
the time of biopsy. Control ®broblasts were obtained by skin biopsy of a
healthy donor (within several days of SSc biopsy); these were matched
with each SSc patient for age, race, gender, and biopsy site and were
processed in parallel. Foreskin ®broblast cultures were established from
newborn foreskins obtained from delivery suites of local hospitals.
Explant tissue was dissociated enzymatically by 0.25% collagenase type I
(Sigma, St. Louis, MO) and 0.05% DNase (Sigma) in Dulbecco's
modi®ed Eagle's medium (DMEM) with 20% fetal bovine serum (FBS)
(GibcoBRL, Grand Island, NY). Cells were grown in DMEM
supplemented with 10% FBS.
Plasmid constructs, transient transfection, and luciferase
assay The COL1A2±luciferase construct contains sequences from ±353
to +58 bp of the human COL1A2 promoter (Ihn et al, 1996) fused to
the luciferase reporter gene (pGL2 basic, Promega, Madison, WI). The
COL1A2±CAT constructs used for deletion and substitution mutant
analyses were described previously (Ihn et al, 1996). For transient
transfection, 60%±80% con¯uent cells in six-well plates were transfected
using FuGENE 6 transfection reagents (Roche Molecular Biochemicals,
Indianapolis, IN) following the manufacturer's recommendations.
Twenty hours later, cells were stimulated with 5 ng per ml TGF-b1
(R&D Systems, Minneapolis, MN) for an additional 24 h. Luciferase
activities in aliquots of equal protein were measured with a dual
luciferase reporter assay system (Promega). A construct containing the
renilla luciferase (pRL-TK, Promega) was cotransfected together with
the collagen promoter and used to control for transfection ef®ciency. In
some experiments 10 mM SB203580 (Biomol, Plymouth Meeting, PA)
was added for 1 h, followed by the addition of TGF-b1. CAT activities
were measured as previously described (Ihn et al, 1996).
Recombinant adenoviruses Replication defective, recombinant
adenoviruses were generated by homologous recombination using a
bacterial system based on the method by Chartier et al (1996). Brie¯y,
the cDNA for the a isoform of mouse p38 or green ¯uorescent protein
(GFP) was cloned into a shuttle plasmid, pAD CMV-Link.1. To
monitor for protein expression, an HA epitope tag was included in the
open reading frame at the amino terminus. For homologous
recombination NheI digested shuttle plasmid was transformed together
with adenoviral plasmid pTG3602 into competent BJ5183 bacterial cells.
Recombinant adenoviral DNA was puri®ed, digested with PacI, and
transfected into the 293 human epithelial kidney (HEK) cell line using
lipofectamine (GibcoBRL). Recombinant adenoviruses were prepared
from plaque lysates and screened for p38 expression by Western blotting.
Following large-scale propagation, adenoviruses were puri®ed by cesium
chloride gradient centrifugation, dialyzed, and titered by plaque assay.
Assay of p38 activation Fibroblasts were transduced with adenoviral
vectors expressing HA tagged p38 or GFP control (100 pfu per cell).
Twenty-four hours later ®broblasts were treated with TGF-b1 (5 ng per
ml). Fibroblasts were lyzed 24 h later and samples were normalized for
protein concentration. Ninety micrograms of protein was immuno-
precipitated with monoclonal anti-HA antibody (Santa Cruz) at a 1:100
dilution overnight at 4°C. Forty microliters of a protein G sepharose
slurry was added while rotating to immunoprecipitate the complexes.
Samples were washed three times, resuspended in sodium dodecyl sulfate
(SDS) sample buffer containing dithiothreitol, and separated by 12% SDS
polyacrylamide gel electrophoresis (PAGE). In indicated experiments
®broblasts were treated with TGF-b1 (5 ng per ml) for various time
intervals, and then lysed in Laemmli sample buffer. Twenty-®ve
micrograms of protein was fractionated by SDS-PAGE. Western blotting
was performed using a 1:1000 dilution of a phospho-speci®c antibody
for p38 (New England Biolabs, Beverly, MA). Speci®c binding of
antibody was detected with a peroxidase-conjugated antirabbit antibody
(1:2000) and visualized by enhanced chemiluminescence (ECL) detection
(Amersham Pharmacia Biotech, Piscataway, NJ). As a loading control,
Western blots were performed using an antibody against total p38 (New
England Biolabs) at a 1:1000 dilution. Western blots for exogenous p38
were performed using a polyclonal antibody against the HA tag (Santa
Cruz) at a 1:1000 dilution. The levels of activated p38 relative to the
levels of total p38 were measured using the NIH Image Densitometry
Software. Quantitative data are presented as the mean 6 SD from three
independent experiments.
RNA preparation and northern blot analysis Con¯uent cells grown
in 60 mm2 dishes were incubated in DMEM/0.1% bovine serum
albumin (BSA) for 24 h. Cells were transduced with adenoviruses for 24
h followed by stimulation with TGF-b1 (5 ng per ml) for an additional
24 h. Total RNA was extracted and analyzed by northern blot as
described previously (Ichiki et al, 1997). Filters were sequentially
hybridized with 32P-labeled probes for proa1(I) collagen, proa2(I)
collagen, and 18S ribosomal RNA. The ®lters were scanned with a
phosphorimager (Molecular Dynamics, Sunnyvale, CA).
Procollagen gel analysis Fibroblasts were plated in 12-well plates and
processed as described previously (Ichiki et al, 1997). Brie¯y, cells were
grown to visual con¯uence, and medium was changed to DMEM
containing 0.1% BSA supplemented with ascorbic acid (50 mg per ml)
for 24 h. Cells were transduced with GFP or p38a adenovirus for 24 h,
followed by 24 h stimulation with TGF-b1 (5 ng per ml). Twenty
microcuries per milliliter of L-[2,3,4,5-3H] proline was added during the
last 24 h of incubation. Aliquots of medium normalized for cell number
were concentrated in a Speed-vac, denatured by boiling in SDS sample
buffer, and separated by 6% SDS-PAGE. After electrophoresis, gels
were enhanced by ¯uorography and visualized by autoradiography.
Collagenous protein levels were quantitated using NIH image.
Quantitative data are presented as the mean 6 SD.
RESULTS
TGF-b activates p38 in dermal ®broblasts Previous studies
have shown that p38 is activated by TGF-b in various epithelial cell
lines (Hanafusa et al, 1999; Sano et al, 1999). To determine whether
p38 is activated by TGF-b in human dermal ®broblasts, we utilized
antibodies speci®c for the phosphorylated form of p38. The early
peak of p38 activation appeared at 2 h (12.2 6 4.5-fold induction)
and activated p38 persisted for 24 h (12.8 6 4.2-fold induction at
8 h, 7.6 6 0.2-fold induction at 24 h) (Fig 1).
SB203580 inhibits type I collagen mRNA induction by
TGF-b The effect of the speci®c pharmacologic inhibitor of p38,
SB203580, on TGF-b induction of collagen type I mRNA was
investigated in dermal ®broblasts (Fig 2). Con¯uent dermal
®broblasts were stimulated with TGF-b for 24 h in the absence
or presence of SB203580 (0.5±10 mM). SB203580 inhibited TGF-
b-stimulated COL1A1 and COL1A2 mRNA levels in a dose-
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dependent manner. The inhibitor treatment had very little effect on
basal collagen mRNA levels.
Human COL1A2 promoter is activated by p38 The collagen
a2(I) (COL1A2) promoter is a widely used experimental model
system to study transcriptional regulation of the collagen type I
gene at the basal level and in response to exogenous stimuli
(Trojanowska et al, 1998; Kouba et al, 1999; Chen et al, 2000;
Zhang et al, 2000). The effect of SB203580 on TGF-b induction of
the ±353 COL1A2 promoter was investigated in dermal ®broblasts
(Fig 3A). Treatment with the inhibitor reduced TGF-b induction
by 53%, suggesting that p38 may be involved in TGF-b regulation
of COL1A2 transcription. As additional signaling pathways may
also be affected by the use of this inhibitor, we utilized a vector
expressing p38a cDNA to further examine the speci®c role of p38.
The COL1A2 promoter was cotransfected with either control
empty vector or p38a expression vector (Fig 3B). Overexpression
of p38a increased the basal activity of the COL1A2 promoter by
6.1 6 0.5-fold. TGF-b and p38a had a synergistic effect on the
COL1A2 promoter activity (21.7 6 3.5-fold induction). Similar
synergistic effects of p38 and TGF-b were also observed with the
p3TP-lux promoter (data not shown). Together, these data suggest
that p38 is a positive mediator of basal and TGF-b-induced
COL1A2 transcription.
Mapping of the p38 response element in the COL1A2
promoter As the expression of p38 in dermal ®broblasts resulted
in a signi®cant potentiation of the TGF-b effects on the COL1A2
promoter, we were interested in further characterization of the
promoter elements mediating the p38 response. We utilized
previously generated deletion constructs of the COL1A2
promoter (Fig 4A) (Tamaki et al, 1995; Ihn et al, 1996). In
agreement with previous studies, progressive deletions of the
COL1A2 promoter decreased basal promoter activity (Fig 4B).
Furthermore, TGF-b stimulation of the promoter gradually
decreased with the removal of a triple Sp1 binding site (±264
deletion) and a CAGA motif (±148 deletion), and was completely
abrogated with the removal of an Sp1 binding site located at ±125
(±108 deletion). These results are in full agreement with previous
studies, which implicated both Sp1 and Smad3 in the TGF-b
stimulation of the COL1A2 promoter (Chen et al, 2000; Zhang
et al, 2000). Stimulation of the COL1A2 promoter by a
combination of p38 and TGF-b followed a pattern similar to
TGF-b stimulation. Modest stimulation was also observed by the
presence of p38 even in the absence of exogenous TGF-b, which
may be due to the previously observed autocrine TGF-b activity in
dermal ®broblasts (Kawakami et al, 1998). Interestingly, however,
stimulation by a combination of p38 and TGF-b was also
consistently observed in a ±108 deletion construct, which may
suggest a possible effect on the components of the basal
transcription machinery.
To further characterize the p38 response element in the
COL1A2 promoter, we utilized previously generated promoter
substitution mutants (Tamaki et al, 1995; Ihn et al, 1996). None of
the substitution mutants fully abolished the stimulatory effects of
the combined action of p38 and TGF-b; however, this response
was greatly diminished in a CAGA-box mutant, which was
previously shown to bind Smad3 (Chen et al, 2000; Zhang et al,
2000), as well as in the Sp1 binding site mutants (Fig 4C). In
contrast, a mutation in the CCAAT motif, which was previously
shown to bind CBF (Ihn et al, 1996; Maity and de Crombrugghe,
1998), greatly diminished basal COL1A2 activity, but did not have
any effect on stimulation with either TGF-b or a combination of
TGF-b and p38. Together, experiments with deletion and
substitution promoter mutants suggest that the p38 pathway affects
formation of a transcription complex containing Smad3 and Sp1,
previously shown to be involved in TGF-b stimulation of the
COL1A2 promoter.
p38 enhances type I collagen mRNA and protein expression
in dermal ®broblasts To examine the role of p38 in the
regulation of endogenous collagen type I genes, we used
adenoviral-mediated gene delivery of p38a into human dermal
®broblasts. Transduction of cells with 10±1000 pfu per cell of
recombinant adenovirus expressing p38a resulted in a dose-
dependent expression of p38 protein as indicated by Western blot
Figure 2. SB203580 inhibits type I collagen mRNA induction by
TGF-b. Dermal ®broblasts were pretreated with indicated doses of
SB203580 for 1 h and stimulated with TGF-b (5 ng per ml) for 24 h.
(A) Northern blot of COL1A1, COL1A2, and 18S RNA from a
representative experiment. (B) Summary of data from three independent
experiments. The graph depicts means 6 SD.
Figure 1. TGF-b activates p38 MAPK in human dermal
®broblasts. Foreskin ®broblasts were incubated with TGF-b (5 ng per
ml) in DMEM supplemented with 0.1% BSA for different periods of
time, as indicated. The levels of activated p38 (p-p38) were determined
by Western blot using a phospho-speci®c antibody. As control, the levels
of total p38 MAPK were determined using a p38-speci®c antibody.
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analysis (Fig 5A). The highest doses of the p38a adenovirus, but
not control adenovirus, were cytotoxic after 48±72 h exposure,
most probably due to the pro-apoptotic function of p38 (Ono and
Han, 2000). Therefore, the 100 pfu per cell concentration was
selected for experiments. This condition allowed > 95% of cells to
be transduced with virus as visualized by expression of GFP. Basal
and TGF-b-stimulated activity of exogenous p38 is shown in
Figure 3. p38a is involved in induction of the COL1A2 promoter
by TGF-b in human dermal ®broblasts. (A) The effect of SB203580
(10 mM) on the activity of the COL1A2-luc promoter in the presence or
absence of TGF-b. (B) The effect of p38a overexpression on the activity
of the COL1A2-luc promoter in the presence or absence of TGF-b.
Transient transfections were performed with the COL1A2-luc promoter
construct (0.9 mg) and either empty vector (pAdTrack-CMV) or p38
expression vector (0.1 mg). The bar graph represents fold induction of
the promoter activity of the promoter construct cotransfected with p38
expression vector relative to the activity of the promoter cotransfected
with empty vector, which was arbitrarily set at 1. The ef®ciency of
transfection was normalized by cotransfection with a construct containing
the renilla luciferase (pRL-TK, Promega). The graph depicts means 6
SD of the COL1A2 promoter activity from three independent
experiments.
Figure 4. Mapping of the p38 response element in the COL1A2
promoter. (A) Schematic representation of the COL1A2 promoter. (B)
Plasmids containing various lengths of the COL1A2 promoter linked to
CAT reporter gene (0.9 mg) were cotransfected with the p38a
expression vector or empty vector (0.1 mg). On the day after
transfection, some wells were incubated with 5 ng per ml of TGF-b,
whereas control wells received medium only. The activity of the ±353
promoter construct cotransfected with empty vector was arbitrarily set at
100. Activities of the promoters from the other experimental conditions
are expressed relative to activity of the unstimulated ±353 promoter
cotransfected with empty vector. (C) The 353COL1A2/CAT construct
containing substitution mutations were analyzed as described in (B). The
graphs depict means 6 SD of the COL1A2 promoter activity from three
to six independent experiments
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Fig 5(B). Ectopic expression of p38 resulted in its activation even
in the absence of TGF-b. Cell viability was not affected under these
conditions as determined by trypan blue exclusion assay (data not
shown). Adenoviral-mediated overexpression of p38a slightly
increased basal COL1A1 and COL1A2 mRNA levels and further
enhanced the stimulatory effects of TGF-b (Fig 5C). The effects of
p38a on the mRNA levels were less pronounced than those
observed with the COL1A2 promoter (Fig 3). It is not uncommon
to observe exaggerated effects in transient transfections compared to
endogenous genes due to the increased copy number of the
promoter sequences per cell. Alternatively, additional post-
transcriptional mechanisms (e.g., effects on mRNA stability) may
be involved.
The effects of p38a on newly synthesized collagenous proteins
were also examined using adenoviral delivery. Consistent with
the mRNA data, p38a resulted in stimulation of the basal and
Figure 5. Adenoviral-mediated expression of p38 induces COL1A1 and COL1A2 mRNA and protein levels. (A) Dose-dependent induction
of p38 protein levels in dermal ®broblasts transduced with increasing doses of adenovirus. Western blot was performed using a p38 antibody as
described in Materials and Methods. (B) Phosphorylation of exogenous p38a expressed via an adenoviral vector. HA tagged p38 (100 pfu per cell) was
immunoprecipitated as described in Materials and Methods. Western blot analysis was performed sequentially using polyclonal antiHA, p38, and p-p38
antibodies as described in Materials and Methods. In parallel, Western blot analysis was performed on total p38 (endogenous + exogenous). (Endogenous
expression of p-p38 was visible after longer exposure.) (C) Northern blot of COL1A1, COL1A2, and 18S RNA in ®broblasts transduced with 100 pfu
per cell adenovirus expressing p38a (p38) or control adenovirus (control). The experiment was repeated three times. Representative data are shown.
(D) Secreted collagenous proteins in cells transduced with p38a or control adenoviruses. Foreskin ®broblasts were incubated in serum-free medium +
ascorbic acid (50 mg per ml) for 24 h and then transduced with AdGFP or Adp38a at equal concentrations. Cells were stimulated with TGF-b (5 ng
per ml) for 24 h followed by addition of 3H proline for an additional 24 h. An aliquot of conditioned medium normalized for cell number was
analyzed via SDS-PAGE.
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TGF-b1-induced levels of secreted collagenous proteins (Fig 5D).
Fibronectin levels were also increased, suggesting that p38 is
involved in the upregulation of other TGF-b-stimulated genes.
Levels and activity of p38 do not differ between SSc and
healthy skin ®broblasts We next examined TGF-b activation
of p38 in ®ve pairs of SSc and healthy skin ®broblasts. All SSc
®broblasts exhibited the activated phenotype characterized by an
elevated production of collagen and ®bronectin (Fig 6A, right
panels, and Fig 6C). The total amounts of p38 were very similar in
SSc and control healthy ®broblasts, and both cell types
demonstrated prolonged activation of p38 up to 24 h similar to
foreskin ®broblasts (Fig 6A, left panels, and Fig 6B). The basal level
of activated p38 was low in both SSc and healthy skin ®broblasts.
Although some variability was observed in basal levels of activated
p38 in SSc ®broblasts compared to healthy controls, there was no
correlation with collagen production. Furthermore, the magnitude
of p38 activation in response to TGF-b appeared to be slightly
decreased in some SSc lines examined in this study (Fig 6).
DISCUSSION
The p38 kinases belong to the MAP kinase family whose members
are characterized by the presence of a dual phosphorylation motif
(Ono and Han, 2000). There are four known members of the p38
subfamily. The p38a and p38b genes are ubiquitously expressed.
p38g is predominantly expressed in muscles, however, and p38d is
developmentally regulated and enriched in some tissues such as
lungs and testis. The upstream dual speci®city kinases including
MAP kinase kinase 6 (MKK6), MKK3, as well as MKK4 activate
p38. There is substrate speci®city for the MKKs; however, MKK6
can activate all four p38 isoforms in vitro (Ono and Han, 2000).
Signi®cantly, TGF-b activated kinase (TAK1) has been shown to
be an upstream activator of MKK6 (Hanafusa et al, 1999).
Activation of this pathway resulted in phosphorylation of activating
transcription factor 2 (ATF-2) and enhancement of the complex
formed between Smad4 and ATF-2. Although Smad proteins are
not direct targets for the p38 pathway, this signaling cascade leads to
activation of the transcription partners for Smads, thus potentiating
the TGF-b response.
This study examined the involvement of the p38 pathway in
TGF-b stimulation of collagen gene expression in dermal
®broblasts. We demonstrate that the p38 pathway is necessary for
collagen gene stimulation by TGF-b. This conclusion is based on
demonstration that inhibition of p38 activity by a speci®c
pharmacologic inhibitor abrogates TGF-b-induced collagen
mRNA levels and COL1A2 promoter activity. Moreover, the
TGF-b response is greatly enhanced by the presence of p38a.
Activation of p38 alone, however, is not suf®cient for collagen
gene induction. We observed high levels of activated exogenous
p38 (Fig 5B) in the absence of TGF-b stimulation, but this
correlated only with modest effects on collagen promoter and
mRNA levels. Consistent with our observations, previous studies
by Reunanen et al (2000) have demonstrated that overexpression of
MKK3 and MKK6 resulted only in a small activation of basal
collagen production in dermal ®broblasts. Collectively, these
observations suggest that activation of p38a is necessary but not
suf®cient for stimulation of collagen production by TGF-b. The
speci®c role of p38a is at present unknown. Signi®cantly, however,
the kinetics of p38 activation by TGF-b correlate well with the
kinetics of TGF-b stimulation of collagen gene expression. It has
been observed that collagen type I mRNA is induced after 3 h post
TGF-b addition and remains elevated for up to 72 h (Ishikawa et al,
1990; Varga et al, 1994). It is possible that p38 contributes to
maintaining the speci®c transcription complexes mediating collagen
gene regulation by TGF-b.
We were also interested in characterizing COL1A2 promoter
elements, which mediate the p38 response. Previous studies have
implicated Smad3 in cooperation with Sp1 as transcription factors
responsible for activation of the COL1A2 promoter by TGF-b
(Zhang et al, 2000). This study suggests that both Sp1 and Smad3
binding sites in the COL1A2 promoter are involved in the p38
response. Neither Smad3 nor Sp1, however, appear to be direct
targets for p38 MAPK. Phosphorylation of these factors is rapidly
and transiently induced by TGF-b with a peak at 30 min and a
decline after 1 h (Czuwara-Ladykowska and Trojanowska, unpub-
lished observations), whereas the peak of p38 induction occurs at
2 h. It is possible that other components of the multiprotein
complex involved in TGF-b stimulation of the collagen gene are
regulated by p38a (Trojanowska, 2002). For example, we have
recently shown that Fli-1 represses basal COL1A2 activity via
interaction with Sp1 (Czuwara-Ladykowska et al, 2001). It is
possible that p38 is involved in inactivating the Fli-1-mediated
repressor complex. Another candidate protein may be CBP/p300,
which was shown to be involved in TGF-b upregulation of
COL1A2 (Ghosh et al, 2000). In future studies, we intend to
characterize the transcription factor, which is targeted by p38a and
is involved in the regulation of the COL1A2 promoter.
Interestingly, out of the three major MAPK signaling cascades,
only p38 appears to have a positive effect on collagen gene
regulation in human dermal ®broblasts. Previous studies have
established that activation of ERK signaling inhibits collagen gene
expression (Reunanen et al, 2000). In agreement with this report,
our recent observations also indicate that ERK is a negative
regulator of TGF-b-induced collagen expression acting at the level
of mRNA stability.1 Recent studies have also demonstrated that
c-Jun, a primary effector of the JNK signaling pathway, inhibits
dermal ®broblast collagen transcription in vitro and in vivo (Davis,
2000; Fisher et al, 2000). Furthermore, c-Jun and JunB were also
shown to block Smad3-mediated transcription in dermal ®broblasts
(Verrecchia et al, 2000). To our knowledge, the role of ERK and
JNK pathways in upregulated collagen production by SSc
®broblasts has not been reported.
SSc ®broblasts are characterized by increased ECM production,
but the mechanism responsible for elevated matrix synthesis is
currently unknown. Previously proposed mechanisms include
activation of autocrine TGF-b (Kawakami et al, 1998), pro-IL-
1a (Kawaguchi et al, 1999), and CTGF pathways (Shi-wen et al,
2000). The goal of this study was to gain additional insight into
collagen gene regulation by TGF-b in dermal ®broblasts and the
possible role of the TGF-b pathway in collagen gene dysregulation
by SSc ®broblasts. The data obtained clearly support the role of
p38a as a positive regulator of collagen synthesis in dermal
®broblasts and a mediator of TGF-b-stimulated ECM production.
It is unlikely, however, that p38 plays a role in elevated ECM
production by SSc ®broblasts. First, SSc and healthy control
®broblasts express similar levels of p38 protein. Second, basal levels
of activated p38 are not consistently increased in SSc ®broblasts.
Elevated basal levels would be expected if this pathway were
responsible for the constitutive upregulation of collagen in these
cells.
Based on the elevated levels of TGF-b receptors in SSc
®broblasts, we have previously proposed that autocrine TGF-b
signaling may be responsible for the abnormal phenotype of SSc
®broblasts (Kawakami et al, 1998). Consistent with this hypothesis,
it was demonstrated that blockade of endogenous TGF-b by
neutralizing anti-TGF-b antibody abrogated upregulated collagen
synthesis by SSc ®broblasts (Ihn et al, 2001). In contrast, our recent
observations indicate that overexpression of the kinase-de®cient
TGF-b receptor type II (TbRIIDk) failed to diminish collagen
production by a large proportion of SSc ®broblasts, but led to a
signi®cant downregulation of collagen production by healthy
dermal ®broblasts.2 Thus, although elevated collagen synthesis by
SSc ®broblasts is TGF-b dependent, the downstream components
1Shegogue D, Trojanowski M: MAPK regulates collagen type 1 mRNA
stability. Mol Biol Cell 10:2429, 1999 (abstr.)
2Gore EA, Smith EA, Rubinchik S, Dong J-Y, Trojanowska M:
Differential regulation of ECM protein synthesis in scleroderma and normal
®broblasts by autocrine TGF-b pathway. Arthritis Rheum 43:1151, 2000
(abstr.)
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Figure 6. TGF-b activates p38 in SSc and healthy skin ®broblasts. (A) Five pairs of SSc and healthy controls were analyzed for total levels of
p38 and activation of p38 in response to TGF-b (5 ng per ml). The levels of activated p38 (p-p38) were determined by Western blot using a phospho-
speci®c antibody. The levels of total p38 MAPK were determined using a p38-speci®c antibody. Collagen protein levels in aliquots of conditioned
medium normalized for cell number were determined by the 3H proline incorporation assay. The left panel represents p38 analyses; the right panel
represents collagen production for the same pair. (B) Graphical analysis of Western blots showing the ratio of p-p38 to total p38 after stimulation with
TGF-b (5 ng per ml). The graphs depict means 6 SD. (C) Graphical analysis of collagenous protein levels comparing normal to SSc. The graphs depict
means 6 SD.
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of the TGF-b pathway, including TbRII and p38, do not appear to
contribute to abnormal collagen production by SSc ®broblasts. It is
possible that the upregulation of collagen synthesis by SSc
®broblasts is mediated through TbRI. It may be relevant that
TGF-b stimulation of proa(I) collagen in rat mesangial cells could
be abrogated by a dominant-negative TbRI, but not by a
dominant-negative TbRII (Chin et al, 2001). Furthermore, other
functions of SSc ®broblasts, such as the recently reported resistance
to Fas-induced apoptosis (Jelaska and Korn, 2000), may depend on
TbRII signaling. Further studies are needed to determine the
speci®c intracellular pathways involved in TGF-b-mediated
upregulation of collagen production by SSc ®broblasts.
This work was supported by NIH grants AR-44883 and AR-42334, and by the
RGK Foundation.
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